The company behind Claude is opening a Bay Area center to integrate AI models with biological experiments in preclinical pharmaceutical research.
Anthropic, the California-based company known for developing the Claude artificial intelligence models, has established its own physical biology laboratory in the San Francisco Bay Area. The facility, revealed by Reuters, represents a significant shift in the use of generative models, which have traditionally been employed to analyze documents or write code.
The goal is to use AI directly in the drug discovery process, linking the work of the models with real-world biological experiments. Claude will be able to formulate hypotheses, analyze data, design experiments, and optimize procedures, while researchers and laboratory equipment will physically test the hypotheses generated by the system.
The project focuses on preclinical research, the stage that precedes human trials. The company has not publicly disclosed all the details about the specific activities of the facility nor indicated any particular drugs in development.
Anthropic is an artificial intelligence company founded in 2021 by former OpenAI researchers, primarily known for developing the Claude family of models. These models are generative AI systems similar to ChatGPT, capable of advanced text understanding and generation. Until now, AIs like Claude have been used mainly for digital tasks: document analysis, code writing, assisting researchers through text-based interfaces.
The pharmaceutical sector has represented a promising field for artificial intelligence application for years, but with significant limitations. Models could suggest potential molecules or analyze data, but there was a lack of a direct and systematic link to experimental verification in the physical world. Hypotheses generated by AI had to go through external laboratories, creating discontinuities in the process.
With this new laboratory, Anthropic takes an evolutionary step: it vertically integrates AI computational capability with direct biological validation. This approach could significantly accelerate preclinical research, reducing the time between hypothesis conception and its experimental verification. The move signals an emerging trend in the sector: AI companies no longer want to be just software tool providers, but direct players in applied scientific research.
"Dentro la Notizia" (Inside the Story) is an amateur, non-profit section of quoz.it, created for people who find it hard to make sense of current affairs without some context. Articles are written with AI assistance from public sources, without a professional newsroom or systematic editorial review: they may contain inaccuracies and are not a substitute for registered news outlets. This is not a registered press outlet under Italian law (L. 62/2001). Images, when not original, come from external sources for illustrative purposes only. If you find an article offensive, inaccurate, or think it should not be published — or you hold rights to a text or image and want it removed — let us know and we will act promptly.
Contact:
info@quoz.it
Comments (0)
No comments yet. Write the first one!